ABEOABEONA THERAPEUTICS INC.

Nasdaq abeonatherapeutics.com


$ 4.42 $ -0.16 (-3.51 %)    

Wednesday, 08-May-2024 15:59:43 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 4.4
$ 4.56
$ 0.00 x 0
$ 0.00 x 0
$ 4.33 - $ 4.58
$ 2.83 - $ 9.01
455,091
na
75.57M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-18-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-29-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 07-28-2021 06-30-2021 10-Q
12 05-17-2021 03-31-2021 10-Q
13 03-24-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-06-2020 03-31-2020 10-Q
17 03-16-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-09-2019 06-30-2019 10-Q
20 05-10-2019 03-31-2019 10-Q
21 03-18-2019 12-31-2018 10-K
22 11-09-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-16-2018 12-31-2017 10-K
26 11-14-2017 09-30-2017 10-Q
27 08-14-2017 06-30-2017 10-Q
28 05-15-2017 03-31-2017 10-Q
29 03-30-2017 12-31-2016 10-K
30 11-14-2016 09-30-2016 10-Q
31 08-15-2016 06-30-2016 10-Q
32 05-16-2016 03-31-2016 10-Q
33 03-30-2016 12-31-2015 10-K
34 11-16-2015 09-30-2015 10-Q
35 08-14-2015 06-30-2015 10-Q
36 05-14-2015 03-31-2015 10-Q
37 03-31-2015 12-31-2014 10-K
38 11-14-2014 09-30-2014 10-Q
39 08-14-2014 06-30-2014 10-Q
40 05-12-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fda-rejects-approval-of-abeona-therapeutics-skin-disorder-treatment-shares-sink

Abeona Therapeutics' pz-cel gets the FDA's Complete Response Letter and Abeona's plans for fulfilling Chemistry Man...

 cantor-fitzgerald-reiterates-overweight-on-abeona-therapeutics-maintains-36-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and maintains $36 pr...

Core News & Articles
Market-Moving News for April 23rd
04/23/2024 12:35:52

ABEO: -55% | Abeona Therapeutics shares are trading lower after the company announced the FDA issued a Complete Response Letter...

 abeona-therapeutics-provides-regulatory-update-on-pz-cel-crl-did-not-identify-deficiencies-related-to-clinical-efficacy-or-clinical-safety-data-in-bla-and-no-new-clinical-studies-requested-by-fda-to-support-approval

Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies rela...

 processa-pharmaceuticals-and-2-other-penny-stocks-insiders-are-buying

The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION